文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

尿液C-C基序趋化因子配体14预测持续性急性肾损伤的性能:系统评价与荟萃分析

Performance of urinary C-C motif chemokine ligand 14 for the prediction of persistent acute kidney injury: a systematic review and meta-analysis.
PubMed 文献 · Crit Care · 2023-08-18
一句话结论系统评价与荟萃分析显示,尿液CCL14预测持续性AKI的汇总敏感度0.81、特异度0.71、阳性似然比2.75、阴性似然比0.27,汇总诊断准确度0.84。

该研究按PRISMA指南检索PubMed、Embase和Cochrane数据库至2023年4月,纳入6项报告尿液CCL14诊断性能的成人(>18岁)研究,共952例患者。患者中持续性AKI发生率为39.6%(377/952)。尿液CCL14预测持续性AKI的汇总敏感度和特异度分别为0.81(95%CI 0.72-0.87)和0.71(95%CI 0.53-0.84),汇总阳性似然比2.75(95%CI 1.63-4.66),阴性似然比0.27(95%CI 0.18-0.41),HSROC汇总诊断准确度0.84。作者认为尿液CCL14可作为预测持续性AKI的有效标志物。

要点

  • 在成人(>18岁)中,尿液CCL14预测持续性AKI的汇总敏感度0.81(95%CI 0.72-0.87)、特异度0.71(95%CI 0.53-0.84)。
  • 汇总阳性似然比2.75(95%CI 1.63-4.66)、阴性似然比0.27(95%CI 0.18-0.41),HSROC汇总诊断准确度0.84。
  • 纳入6项研究共952例患者,持续性AKI发生率为39.6%(377/952)。
  • 作者认为尿液CCL14可作为预测持续性AKI的有效标志物。

适用人群与场景

  • 成人(>18岁)、报告尿液CCL14诊断性能的研究人群。

研究设计与关键结果

  • 系统评价与荟萃分析,按PRISMA指南检索PubMed、Embase和Cochrane数据库至2023年4月,纳入6项研究共952例成人(>18岁)患者。
  • 持续性AKI发生率为39.6%(377/952)。
  • 尿液CCL14预测持续性AKI的汇总敏感度0.81(95%CI 0.72-0.87)、特异度0.71(95%CI 0.53-0.84)。
  • 汇总阳性似然比2.75(95%CI 1.63-4.66)、阴性似然比0.27(95%CI 0.18-0.41)。
  • HSROC汇总诊断准确度0.84。

证据类型、等级与局限

  • 系统评价与荟萃分析,采用GRADE标准评价证据质量。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为尿液CCL14可作为预测持续性AKI的有效标志物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Urinary C-C motif chemokine ligand 14 (CCL14) has been described as an effective marker for delayed recovery of acute kidney injury (AKI), yet its efficacy has been found to vary between different trials. The goal of this research was to assess the predictive performance of urinary CCL14 as a marker for persistent AKI.

METHODS: In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched the PubMed, Embase, and Cochrane databases up to April 2023 for studies of adults (> 18 years) that reported the diagnostic performance of urinary CCL14. The sensitivity, specificity, number of events, true positive, and false positive results were extracted and evaluated. Hierarchical summary receiver operating characteristic curves (HSROCs) were used to summarize the pooled test performance, and the Grading of Recommendations, Assessment, Development and Evaluations criteria were used to appraise the quality of evidence.

RESULTS: We included six studies with 952 patients in this meta-analysis. The occurrence of persistent AKI among these patients was 39.6% (377/952). The pooled sensitivity and specificity results of urinary CCL14 in predicting persistent AKI were 0.81 (95% CI 0.72-0.87) and 0.71 (95% CI 0.53-0.84), respectively. The pooled positive likelihood ratio (LR) was 2.75 (95% CI 1.63-4.66), and the negative LR was 0.27 (95% CI 0.18-0.41). The HSROC with pooled diagnostic accuracy was 0.84.

CONCLUSION: Our results suggest that urinary CCL14 can be used as an effective marker for predicting persistent AKI.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Chen YT, Pan HC, Hsu CK, et al. Performance of urinary C-C motif chemokine ligand 14 for the prediction of persistent acute kidney injury: a systematic review and meta-analysis. Crit Care. 2023. PMID: 37596698. doi:10.1186/s13054-023-04610-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。